Replies to post #43113 on OncoSec Medical Inc (ONCSQ)

[trading.jeff]

$ONCS Nice action for the first five minutes. Earnings report after the market closes today. Don't think there will be any revenue or profits, as in past ERs, but what is different is the pps is running on "anticipation" of future positive events and results from the trials.

[hschlauch]

The forthcoming TNBC data remind me of the Immunopulse IL-12 monotherapy trial where patients going directly from IL-12 to anti-PD-1 agents had profound responses in advanced melanoma. That trial demonstrated around 75% ORR and I think 50% complete responders in the subset. I'm not saying the TNBC study will observe those same percentages - after all, the trial is tiny and only designed for immune monitoring data, but there might be some very tantalizing data coming out next month. To maintain perspective, approximately 5% of heavily pretreated TNBC patients respond to anti-PD-1 or anti-PD-L1 agents and the complete response rate is well below 1%.

There is likely a very good reason why O'Connor wants to advance TAVO quickly through a combination study in TNBC.